Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Two-year Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity

Trial Profile

Two-year Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Acronyms STEP 5
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 24 Aug 2023 Results assessing effect of semaglutide on 10-year type 2 diabetes risk in adults with overweight or obesity in STEP1 & STEP 5 studies, published in the Obesity (Silver Spring, Md.)
    • 01 Oct 2022 Results assessing efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term treatment of adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes, published in the Nature Medicine.
    • 23 Sep 2022 Results of post hoc analysis assessing Impact of once weekly subcutaneous semaglutide 2.4 mg on metabolic syndrome in the 2-year, presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top